Boston Scientific (BSX, Financial) saw its shares rise nearly 5%, reaching a new all-time high of $96.42. The surge followed the announcement of its agreement to acquire Bolt Medical, Inc. The company anticipates the transaction will be finalized in the first half of 2025, pending the satisfaction of customary closing conditions.
Boston Scientific expects the acquisition to have a slight dilutive effect on its earnings per share (EPS) in 2025. However, the company plans to offset this impact through internal cost efficiencies and strategic adjustments. This acquisition aligns with Boston Scientific's strategy to expand its portfolio and enhance its market position.
